Citi raised the firm’s price target on Biogen (BIIB) to $153 from $135 and keeps a Neutral rating on the shares. The firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of a Q3 earnings preview. The group is well positioned into the second half of 2025 and 2026 as policy overhangs ease and investor focus returns to fundamentals, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $149 from $144 at Morgan Stanley
- Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies
- Stoke, Biogen presents new data from OLE studies of zorevunersen
- Eisai, Biogen announces Leqembi Iqlik availability in the U.S.
- Eisai, Biogen announce U.S. availability of LEQEMBI IQLIK